Develop innovative animal health products sourced from partially de-risked human therapeutic pipelines.
Through a collaborative, joint venture–driven approach, each program is structured and funded independently within dedicated special purpose vehicles (SPVs), enabling focused development and capital efficiency. This model generates accretive scientific and financial value for both human life sciences partners and animal health investors, while providing clear, program-by-program pathways to strategic exit.